Abstract:Background: Iron oxide nanoparticles (IONPs) have been cleared by the Food and Drug Administration (FDA) for various clinical applications, such as tumor-targeted imaging, hyperthermia therapy, drug delivery, and live-cell tracking. However, the application of IONPs as T1 contrast agents has been restricted due to their high r2 values and r2/r1 ratios, which limit their effectiveness in T1 contrast enhancement. Notably, IONPs with diameters smaller than 5 nm, referred to as extremely small-sized IONPs (ESIONs), have demonstrated potential in overcoming these limitations. To advance the clinical application of ESIONs as T1 contrast agents, we have refined a scale-up process for micelle encapsulation aimed at improving the hydrophilization of ESIONs, and have carried out comprehensive in vivo biodistribution and preclinical toxicity assessments. Results: The optimization of the scale-up micelle-encapsulation process, specifically employing Tween60 at a concentration of 10% v/v, resulted in ESIONs that were uniformly hydrophilized, with an average size of 9.35 nm and a high purification yield. Stability tests showed that these ESIONs maintained consistent size over extended storage periods and dispersed effectively in blood and serum-mimicking environments. Relaxivity measurements indicated an r1 value of 3.43 mM- 1s- 1 and a favorable r2/r1 ratio of 5.36, suggesting their potential as T1 contrast agents. Biodistribution studies revealed that the ESIONs had extended circulation times in the bloodstream and were primarily cleared via the hepatobiliary route, with negligible renal excretion. We monitored blood clearance and organ distribution using positron emission tomography and magnetic resonance imaging (MRI). Additionally, MRI signal variations in a dose-dependent manner highlighted different behaviors at varying ESIONs concentrations, implying that optimal dosages might be specific to the intended imaging application. Preclinical safety evaluations indicated that ESIONs were tolerable in rats at doses up to 25 mg/kg. Conclusions: This study effectively optimized a scale-up process for the micelle encapsulation of ESIONs, leading to the production of hydrophilic ESIONs at gram-scale levels. These optimized ESIONs showcased properties conducive to T1 contrast imaging, such as elevated r1 relaxivity and a reduced r2/r1 ratio. Biodistribution study underscored their prolonged bloodstream presence and efficient clearance through the liver and bile, without significant renal involvement. The preclinical toxicity tests affirmed the safety of the ESIONs, supporting their potential use as T1 contrast agent with versatile clinical application.

Gram-Scale Preparation of Iron Oxide Nanoparticles with Renal Clearance Properties for Enhanced T1-Weighted Magnetic Resonance Imaging.

Continuous Synthesis of Extremely Small-Sized Iron Oxide Nanoparticles Used for T1-weighted Magnetic Resonance Imaging Via a Fluidic Reactor

Moderate Cooling Coprecipitation for Extremely Small Iron Oxide As a Ph Dependent T1-MRI Contrast Agent.

Renal-clearable zwitterionic conjugated hollow ultrasmall Fe 3 O 4 nanoparticles for T 1 -weighted MR imaging in vivo.

Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging.

Ultracompact Iron Oxide Nanoparticles with a Monolayer Coating of Succinylated Heparin: A New Class of Renal-Clearable and Nontoxic T1 Agents for High-Field MRI.

Hydrothermal synthesis of a highly sensitive T2-weigthed MRI contrast agent: zinc-doped superparamagnetic iron oxide nanocrystals.

Ultrasmall Water-Soluble Metal-Iron Oxide Nanoparticles As T1-weighted Contrast Agents for Magnetic Resonance Imaging.

Optimization of micelle-encapsulated extremely small sized iron oxide nanoparticles as a T1 contrast imaging agent: biodistribution and safety profile

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Extremely Small Iron Oxide Nanoparticles with Ph-Dependent Solubility Transition As T1/T2 Switchable Contrast Agents for MRI

One pot synthesis of zwitteronic 99mTc doped ultrasmall iron oxide nanoparticles for SPECT/T1-weighted MR dual-modality tumor imaging

Albumin-constrained large-scale synthesis of renal clearable ferrous sulfide quantum dots for T1-Weighted MR imaging and phototheranostics of tumors

Ultrasmall Water‐Soluble and Biocompatible Magnetic Iron Oxide Nanoparticles As Positive and Negative Dual Contrast Agents

Biodegradable and Renal-Clearable Hollow Porous Iron Oxide Nanoboxes for in Vivo Imaging

Facile Synthesis of Zinc Ferrite Nanoparticles As Non-Lanthanide T-1 Mri Contrast Agents

Silica-coated Super-Paramagnetic Iron Oxide Nanoparticles (spionps): a New Type Contrast Agent of T1 Magnetic Resonance Imaging (MRI).

Europium-engineered Iron Oxide Nanocubes with High T1 and T2 Contrast Abilities for MRI in Living Subjects.

Ultrasmall Superparamagnetic Iron Oxide Nanoparticle for T2-Weighted Magnetic Resonance Imaging.

Octapod iron oxide nanoparticles as high-performance T 2 contrast agents for magnetic resonance imaging

Transition metal doped hydrophilic ultrasmall iron oxide modulate MRI contrast performance for accurate diagnosis of orthotopic prostate cancer